Mortality within 24 hours of thrombolysis for myocardial infarction: The importance of early reperfusion

Circulation

Volumn 90, Issue 6, 1994, Pages 2658-2665

  Kleiman, Neal S ^a,j   White, Harvey D ^b   Ohman, E Magnus ^c   Ross, Allan M ^d   Woodlief, Lynn H ^c   Califf, Robert M ^c   Holmes Jr , David R ^e   Bates, Eric ^f   Pfisterer, Matthias ^g   Vahanian, Alec ^h   Topol, Eric J ⁱ  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b GREEN LANE HOSPITAL   (New Zealand)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

^h HÔPITAL TENON   (France)

ⁱ LERNER RESEARCH INSTITUTE   (United States)

^j HOUSTON METHODIST HOSPITAL   (United States)

more..

Author keywords

infarction; mortality; reperfusion; tamponade; thrombolysis

Indexed keywords

ALTEPLASE; HEPARIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; ATRIOVENTRICULAR BLOCK; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEART DEATH; HEART INFARCTION; HEART REINFARCTION; HEART TAMPONADE; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINUS TACHYCARDIA; SMOKING; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0028641554     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.cir.90.6.2658     Document Type: Article

References (18)

1. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
2. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1:397-401.
3. ISIS-2 (Second International Study of Infarct Survival). Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. ISIS 2. Lancet. 1988;2:349-360.
4. Wilcox R, Olsson C, Skene A, Von Der Lippe G, Jensen G, Hampton J. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo Scandinavian Study of Early Thrombolysis (ASSET). Lancet. 1988;2:525-530.
5. Mauri F, DeBiase A, Franzosi M, Pampallona S, Foresti A, Gasparini M. Analisi dele casue di morte intraospedaliera. G Ital Cardiol. 1987;17:37-44.
6. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 1994;343:311-322.
7. Kleiman N, Terrin M, Mueller H, Chaitman B, Roberts R, Braunwald E, Knatterud G, Solomon R, McMahan R, and the TIMI Investigators. Mechanisms of early death despite thrombolytic therapy: experience from the Thrombolysis in Myocardial Infarction phase II (TIMI II) study. J Am Coll Cardiol. 1992;19: 1129-1135.
8. Maynard C, Weaver D, Litwin P, Martin J, Kudenchuk P, Dewhurst T, Eisenberg M, Hallstrom A, Chambers J, MITI Project Investigators. Hospital mortality in acute myocardial infarction in the era of reperfusion therapy (the Myocardial Infarction Triage and Intervention Project) (MITI). Am J Cardiol. 1993;72:877-882.
9. Ohman E, Topol E, Califf R, Bates E, Ellis S, Kereiakes D, George B, Samaha J, Kline E, Sigmon K, Stack R, and the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. An analysis of the cause of early mortality after administration of thrombolytic therapy. Coron Artery Dis. 1993;4:957-964.
10. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993;329:1615-1622.
11. Chesebro J, Knatterud G, Roberts R, Borer J, Cohen L, Dalen J, Dodge H, Francis C, Hillis D, Ludbrook P, Markis J, Mueller H, Passamani E, Powers E, Rao A, Robertson T, Ross A, Ryan T, Sobel B, Willerson J, Williams D, Zaret B, Braunwald E. Thrombolysis in Myocardial Infarction (TIMI) trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation. 1987;76:142-154.
12. ISIS-1 (First International Study of Infarct Survival Collaborative Group). Mechanisms for the early mortality reduction produced by beta blockade started early in acute myocardial infarction: ISIS-1. Lancet. 1988;1:921-923.
13. Waller B, Rothbaum D, Pinkerton C, Cowley M, Linnemeier T, Orr C, Irons M, Helmuth R, Wills E, Aust C. Status of the myocardium and infarct-related coronary artery in 19 necropsy patients with acute recanalization using pharmacologic (streptokinase, r-tissue plasminogen activator), mechanical (percutaneous transluminal coronary angioplasty) or combined types of reperfusion therapy. J Am Coll Cardiol. 1987;9:785-801.
14. Honan M, Harrell F, Reimer K, Califf R, Mark D, Pryor D, Hlatky M. Cardiac rupture, mortality and the timing of thrombolytic therapy: a meta-analysis. J Am Coll Cardiol. 1990;16:359-367.
15. Oliva P, Hammill S, Edwards W. Cardiac rupture, a clinically predictable complication of acute myocardial infarction: report of 70 cases with clinicopathologic correlations. J Am Coll Cardiol. 1993;22:720-726.
16. Mueller H, Rao A, Forman S, TIMI Investigators. Thrombolysis in Myocardial Infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator. J Am Coll Cardiol. 1987; 10:479-490.
17. Braunwald E, Kloner R. Prolonged postischemic ventricular dysfunction. Circulation. 1982;66:1146-1149.
18. Ganz W, Geft I, Shah P, Lew A, Rodriguez L, Wei T, Maddahi J, Berman D, Charuzi Y, Swan H. Intravenous streptokinase in evolving acute myocardial infarction. Am J Cardiol. 1984;53:1209.